LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer

• Verfasst von: Sas-Chen, Aldema [VerfasserIn]
• Verfasst von: Polycarpou-Schwarz, Maria [VerfasserIn]
• Verfasst von: Diederichs, Sven [VerfasserIn]
• Titel: LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer
• Verf.angabe: Aldema Sas‐Chen, Miriam R Aure, Limor Leibovich, Silvia Carvalho, Yehoshua Enuka, Cindy Körner, Maria Polycarpou‐Schwarz, Sara Lavi, Nava Nevo, Yuri Kuznetsov, Justin Yuan, Francisco Azuaje, Igor Ulitsky, Sven Diederichs, Stefan Wiemann, Zohar Yakhini, Vessela N Kristensen, Anne‐Lise Børresen‐Dale, Yosef Yarden, Torill Sauer, Jürgen Geisler, Solveig Hofvind, Tone F Bathen, Elin Borgen, Olav Engebråten, Øystein Fodstad, Øystein Garred, Gry Aarum Geitvik, Rolf Kåresen, Bjørn Naume, Gunhild Mari Mælandsmo, Hege G Russnes, Ellen Schlichting, Therese Sørlie, Ole Christian Lingjærde, Kristine Kleivi Sahlberg, Helle Kristine Skjerven and Britt Fritzman
• E-Jahr: 2016
• Jahr: 1 August 2016
• Umfang: 13 S.
• Fussnoten: Gesehen am 10.01.2018
• Titel Quelle: Enthalten in: European Molecular Biology OrganizationEMBO molecular medicine
• Ort Quelle: [London] : Nature Publishing Group UK, 2009
• Jahr Quelle: 2016
• Band/Heft Quelle: 8(2016), 9, Seite 1052-1064
• ISSN Quelle: 1757-4684
• DOI: doi:10.15252/emmm.201606198
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1567010555

Abstract

Long noncoding RNAs (lncRNAs) are emerging as regulators of gene expression in pathogenesis, including cancer. Recently, lncRNAs have been implicated in progression of specific subtypes of breast cancer. One aggressive, basal‐like subtype associates with increased EGFR signaling, while another, the HER2‐enriched subtype, engages a kin of EGFR. Based on the premise that EGFR‐regulated lncRNAs might control the aggressiveness of basal‐like tumors, we identified multiple EGFR‐inducible lncRNAs in basal‐like normal cells and overlaid them with the transcriptomes of over 3,000 breast cancer patients. This led to the identification of 11 prognostic lncRNAs. Functional analyses of this group uncovered LINC01089 (here renamed LncRNA Inhibiting Metastasis; LIMT), a highly conserved lncRNA, which is depleted in basal‐like and in HER2‐positive tumors, and the low expression of which predicts poor patient prognosis. Interestingly, EGF rapidly downregulates LIMT expression by enhancing histone deacetylation at the respective promoter. We also find that LIMT inhibits extracellular matrix invasion of mammary cells in vitro and tumor metastasis in vivo. In conclusion, lncRNAs dynamically regulated by growth factors might act as novel drivers of cancer progression and serve as prognostic biomarkers.